French pharmaceutical company Sanofi on Tuesday announced a partnership with ChatGPT founder OpenAI and US biotech company Formation Bio to accelerate the use of artificial intelligence in drug development.
AI is playing an increasing role not only in developing new drugs but also in identifying new uses for existing drugs.
For example, it can be used to discover new molecules faster or improve clinical tests by scrutinizing which patients are most likely to respond to treatment.
Formation Bio CEO Benjamin Liu said that by combining their resources, the three companies could “reimagine drug development in the pharmaceutical industry.”
Sanofi has collaborated on AI in recent years with biotech companies including Owkin, Exscientia, Insilico Medicine, Amunix Pharmaceuticals, Atomwise, and Aqemia.
“The three teams will integrate data, software and tailored models to develop customized and purpose-built solutions across the drug development lifecycle,” Sanofi said in a statement.
“Sanofi will leverage this partnership to provide access to unique data, develop AI models, and continue on our path to becoming the first biopharmaceutical company to leverage AI at scale.” Stated.
OpenAI “will contribute access to cutting-edge AI capabilities, including the ability to fine-tune models, deep AI expertise, and dedicated thought partnerships and resources.”
